Many hands make light work: CNV of GSTM1 effect on the oral carcinoma risk

Imagem de Miniatura
Arquivos
art_FIRIGATO_Many_hands_make_light_work_CNV_of_GSTM1_2022.PDF (411.22 KB)
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCI LTD
Autores
CURIONI, Otavio A.
ANTONIO, Juliana De
Citação
CANCER EPIDEMIOLOGY, v.78, article ID 102150, 6p, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Genetic alterations of oral squamous cell carcinoma (OSCC) allow the understanding of the oral carcinogenesis and the identification of molecular biomarkers that aid the early diagnosis of the disease. The copy number variation (CNV) of GSTM1 and GSTT1 are promising targets because these two genes codify enzymes that perform the inactivation of tobacco carcinogens, which are the main risk factor of OSCC. However, the different levels of - detoxification mechanism in relation to each copy of the genes are unknown. Therefore, this study aimed to investigate the possible association of the CNV of GSTM1 and GSTT1 with the risk of development of OSCC. Methods: A total of 234 OSCC patients and 422 patients without any cancer diagnoses were recruited from Heli acute accent opolis Hospital from 2000 to 2011. The CNV was determined by TaqMan real-time PCR and the CopyCaller software. Odds ratio (OR) and 95% confidence interval (95% CI) values were calculated by Multiple Logistic Regression. Results: Most OSCC patients reported they continued smoking high amounts of cigarettes despite the tumor diagnosis. The CNV of GSTM1 varied from zero to two copies and the analysis revealed that two copies of GSTM1 decreased by 53% the OSCC risk (OR 0.47; 95% CI 0.24-0.92) and the risk of the tumor was modified according to the interaction of the CNV of GSTM1 and the cigarette smoking consumption, which for the amount of 40 packs-year of cigarettes the OSCC risk diminished progressively according to the increase of copies of GSTM1. Although the GSTT1 gene varied from zero to three copies, none of them were associated with the tumor risk. Conclusion: The findings suggest that the CNV of GSTM1 might be applied as a tool for the surveillance of patients and the early detection of OSCC.
Palavras-chave
GSTM1, Copy number variation, Oral squamous cell carcinoma, Cancer susceptibility
URI
https://observatorio.fm.usp.br/handle/OPI/47147
Referências
  1. Ali J, 2017, ORAL ONCOL, V70, P23, DOI 10.1016/j.oraloncology.2017.05.004
  2. Almal SH, 2012, J HUM GENET, V57, P6, DOI 10.1038/jhg.2011.108
  3. Bagan J, 2010, ORAL ONCOL, V46, P414, DOI 10.1016/j.oraloncology.2010.03.009
  4. Boing AF, 2011, CIENC SAUDE COLETIVA, V16, P615, DOI 10.1590/S1413-81232011000200025
  5. Brasch-Andersen C, 2004, HUM MUTAT, V24, P208, DOI 10.1002/humu.20074
  6. Chaturvedi P, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l2142
  7. Conway DI, 2018, BRIT DENT J, V225, P867, DOI 10.1038/sj.bdj.2018.922
  8. Curioni O.A., 2013, J CANC THER, V04, P978, DOI [10.4236/jct.2013.45112, DOI 10.4236/JCT.2013.45112, DOI 10.4236/jct.2013.45112]
  9. Emeville E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107275
  10. Ferlay J, 2021, INT J CANCER, V149, P778, DOI 10.1002/ijc.33588
  11. Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857
  12. Hayes JD, 2000, PHARMACOLOGY, V61, P154, DOI 10.1159/000028396
  13. Hopkins J, 2008, CANCER EPIDEM BIOMAR, V17, P490, DOI 10.1158/1055-9965.EPI-07-2714
  14. Jancova P, 2010, BIOMED PAP, V154, P103, DOI 10.5507/bp.2010.017
  15. Karageorgi S, 2011, CANCER EPIDEM BIOMAR, V20, P1447, DOI 10.1158/1055-9965.EPI-11-0190
  16. Li Chia-Cheng, 2018, Dent Clin North Am, V62, P29, DOI 10.1016/j.cden.2017.08.002
  17. McCarroll SA, 2006, NAT GENET, V38, P86, DOI 10.1038/ng1696
  18. McLellan RA, 1997, MOL PHARMACOL, V52, P958, DOI 10.1124/mol.52.6.958
  19. MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
  20. Min SK, 2019, ORAL ONCOL, V95, P16, DOI 10.1016/j.oraloncology.2019.05.025
  21. Ministerio da Sade, NO TITLE
  22. Nowakowska B, 2017, J APPL GENET, V58, P449, DOI 10.1007/s13353-017-0407-4
  23. Rivera C, 2015, INT J CLIN EXP PATHO, V8, P11884
  24. Saitou M, 2018, BMC GENOMICS, V19, DOI 10.1186/s12864-018-4676-z
  25. Saitou Marie, 2015, Asian Pac J Cancer Prev, V16, P355
  26. Speleman F, 2008, CYTOGENET GENOME RES, V123, P176, DOI 10.1159/000184706
  27. Sprenger R, 2000, PHARMACOGENETICS, V10, P557, DOI 10.1097/00008571-200008000-00009
  28. Sudmant PH, 2015, SCIENCE, V349, DOI 10.1126/science.aab3761
  29. U.S. Department of Health and Human Services, 2010, TOB SMOK CAUS DIS BI
  30. Wu BJ, 2012, TRENDS PHARMACOL SCI, V33, P656, DOI 10.1016/j.tips.2012.09.007
  31. Zarrei M, 2015, NAT REV GENET, V16, P172, DOI 10.1038/nrg3871

Coleções
Artigos e Materiais de Revistas Científicas - FM/MLS
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - LIM/38
Artigos e Materiais de Revistas Científicas - LIM/40
Artigos e Materiais de Revistas Científicas - ODS/03
Carregar mais